Tirzepatide Injection: What the Research Shows

The short version

Tirzepatide injection is administered subcutaneously (under the skin) once per week. The once-weekly schedule is possible because of a fatty-acid chain attached to the peptide that causes it to bind to a protein in the blood (albumin), slowing its removal from the body to produce an approximately five-day half-life.

In clinical trials, participants started at 2.5 mg per week and gradually stepped up to 5, 7.5, 10, 12.5, and then 15 mg over 20 weeks — with most patients settling at 10 or 15 mg as the long-term dose. The slow escalation was designed to reduce nausea and other stomach symptoms that occur when the drug is started at full dose. The injection itself goes into the thigh, abdomen, or upper arm, with site rotation recommended. This page summarizes the pharmacokinetic and administration data from the published research.

Tirzepatide injection route and pharmacokinetics

Subcutaneous injection is the only route used in the approved and clinical-trial programme. The tirzepatide injection formulation is a solution delivered via single-dose auto-injector or prefilled pen per the prescribing information ^[16]. Subcutaneous injection into the abdominal region, thigh, or upper arm are the approved injection sites; sites should be rotated to reduce injection site reactions ^[16].

The pharmacokinetic basis of once-weekly dosing: tirzepatide's 39-amino-acid peptide backbone would be cleared from circulation within hours if injected unmodified, like most small peptides. The C20 fatty-diacid modification changes that. By binding reversibly to albumin in plasma, tirzepatide is effectively given a reservoir that releases it slowly. The measured elimination half-life in humans is approximately five days, enabling the drug to maintain therapeutic concentrations for a full week between injections ^[1].

The discovery paper's phase 1 programme (Coskun 2018) in 142 subjects (healthy volunteers and type 2 diabetes patients) confirmed the pharmacokinetics supporting once-weekly dosing and showed reduced fasting glucose and body weight versus placebo at tirzepatide doses ^[1]. These phase 1 pharmacokinetic results directly informed the once-weekly schedule used across all subsequent SURPASS and SURMOUNT trials.

Gastric emptying delay — what the research shows

A dedicated pharmacokinetic study (Urva 2020) characterized tirzepatide's effect on gastric emptying using a validated scintigraphy method in type 2 diabetes patients. The study found that tirzepatide transiently delays gastric emptying at the same magnitude as selective long-acting GLP-1 receptor agonists, but the effect attenuates with continued exposure as the body adapts to the sustained drug level ^[24].

The gastric emptying delay has practical clinical implications documented in a dedicated review (Jalleh 2024): because tirzepatide slows the movement of food from the stomach into the small intestine, co-administered oral medications are absorbed more slowly. The prescribing information specifically notes reduced effectiveness of oral hormonal contraceptives as a consequence ^[16]. The label advises using a non-oral or barrier contraceptive method during the initial 4 weeks of tirzepatide and after each dose increase, when the gastric-emptying effect is greatest ^[16].

The gastric-emptying effect also creates a risk during procedures requiring sedation or general anesthesia. Because tirzepatide slows gastric motility and has a five-day half-life (meaning significant drug levels are present for weeks after the last dose), retained gastric contents are a theoretical aspiration risk. Published reviews propose extended fasting periods, point-of-care gastric ultrasound, or prokinetic medications before scheduled procedures; however, the evidence for a specific fasting protocol is limited and documented aspiration events remain rare ^[23].

What the injection data shows about timing and tolerability

Once-weekly tirzepatide injection can be given on any day of the week and at any time of day, with or without food. If a dose is missed by more than four days, the missed dose should be skipped; if missed by four days or fewer, the missed dose can be given and the regular weekly schedule resumed ^[16].

Injection-site reactions — redness, tenderness, bruising, or small nodules — are the second most frequently reported adverse event category in real-world pharmacovigilance data, accounting for a large proportion of spontaneous reports in the FDA Adverse Event Reporting System (FAERS) analyses ^[32][13]. Rotation of injection sites is the primary mitigation strategy documented in both the prescribing information and published pharmacovigilance analyses.

Gastrointestinal adverse events associated with the tirzepatide injection programme — nausea, vomiting, diarrhea, constipation — are dose-related and most frequent during the escalation from each dose step, typically peaking in the first one to two weeks at each new level. The 20-week titration schedule used in the SURPASS and SURMOUNT trials was designed specifically to allow the GI tract to adapt before each increase ^[4][12][14].